Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2012

Open Access 01-12-2012 | Correspondence

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

Authors: Douglas G Altman, Lisa M McShane, Willi Sauerbrei, Sheila E Taube

Published in: BMC Medicine | Issue 1/2012

Login to get access

Abstract

Background

The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist consists of 20 items to report for published tumor marker prognostic studies. It was developed to address widespread deficiencies in the reporting of such studies. In this paper we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report.

Methods

REMARK recommends including a transparent and full description of research goals and hypotheses, subject selection, specimen and assay considerations, marker measurement methods, statistical design and analysis, and study results. Each checklist item is explained and accompanied by published examples of good reporting, and relevant empirical evidence of the quality of reporting. We give prominence to discussion of the 'REMARK profile', a suggested tabular format for summarizing key study details.

Summary

The paper provides a comprehensive overview to educate on good reporting and provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general.
To encourage dissemination of the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration, this article has also been published in PLoS Medicine.
Appendix
Available only for authorised users
Literature
1.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005, 93: 387-391.PubMedPubMedCentral
2.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005, 97: 1180-1184.PubMed
3.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005, 41: 1690-1696.PubMed
4.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005, 23: 9067-9072.PubMed
5.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005, 2: 416-422.PubMed
6.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006, 100: 229-235.PubMed
7.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol. 2006, 28: 99-105.PubMed
8.
Moher D, Schulz KF, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001, 285: 1987-1991.PubMed
9.
Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007, 4: e297.PubMedPubMedCentral
10.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6: e1000100.PubMedPubMedCentral
11.
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c869.PubMedPubMedCentral
12.
13.
Altman DG, Lyman GH: Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat. 1998, 52: 289-303.PubMed
14.
Hall PA, Going JJ: Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology. 1999, 35: 489-494.PubMed
15.
Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA: Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003, 88: 1191-1198.PubMedPubMedCentral
16.
Sauerbrei W: Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Adv Otorhinolaryngol. 2005, 62: 184-200.PubMed
17.
Kyzas PA, Loizou KT, Ioannidis JP: Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005, 97: 1043-1055.PubMed
18.
Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007, 99: 236-243.PubMed
19.
Riley RD, Sauerbrei W, Altman DG: Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009, 100: 1219-1229.PubMedPubMedCentral
20.
Mallett S, Timmer A, Sauerbrei W, Altman DG: Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer. 2010, 102: 173-180.PubMed
21.
Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP: New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. Pancreas. 2011, 40: 522-532.PubMed
22.
Egger M, Juni P, Bartlett C: Value of flow diagrams in reports of randomized controlled trials. JAMA. 2001, 285: 1996-1999.PubMed
23.
Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c332.PubMedPubMedCentral
24.
Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S, Landberg G: Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst. 2009, 101: 1725-1729.PubMed
25.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964.PubMed
26.
Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000, 92: 1805-1811.PubMed
27.
Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN: Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009, 24: 1-10.PubMed
28.
Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004, 22: 529-536.PubMed
29.
Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG: Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer. 1999, 79: 300-307.PubMedPubMedCentral
30.
Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008, 26: 4595-4602.PubMedPubMedCentral
31.
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB: Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009, 15: 5258-5266.PubMedPubMedCentral
32.
Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK: Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005, 23: 8313-8321.PubMed
33.
Burton A, Altman DG: Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer. 2004, 91: 4-8.PubMedPubMedCentral
34.
de Mascarel I, Bonichon F, Durand M, Mauriac L, MacGrogan G, Soubeyran I, Picot V, Avril A, Coindre JM, Trojani M: Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998, 34: 58-65.PubMed
35.
Cho H, Kang ES, Kim YT, Kim JH: Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest. 2009, 27: 313-323.PubMed
36.
Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Muller-Hermelink HK, Ott G, Rosenwald A, Campo E: Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol. 2008, 26: 4966-4972.PubMed
37.
Djidja MC, Claude E, Snel MF, Scriven P, Francese S, Carolan V, Clench MR: MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. J Proteome Res. 2009, 8: 4876-4884.PubMed
38.
39.
Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD: Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol. 2008, 26: 5638-5644.PubMedPubMedCentral
40.
International Society for Biological and Environmental Repositories (ISBER): 2008 Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Cell Preserv Technol. 2008, 6: 5-58.
41.
Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hainaut P, Hayes DF, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J: Biospecimen reporting for improved study quality (BRISQ). Biopreservation Biobanking. 2011, 9: 57-70.PubMedPubMedCentral
42.
Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M: Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003, 16: 173-182.PubMed
43.
Hammond ME, Barker P, Taube S, Gutman S: Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol. 2003, 11: 103-106.PubMed
44.
van den Broek LJCM, van de Vijver MJ: Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol. 2000, 8: 316-321.PubMed
45.
Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME: Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004, 13: 667-672.PubMed
46.
Ransohoff DF: Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005, 5: 142-149.PubMed
47.
Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M: p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009, 15: 2116-2122.PubMedPubMedCentral
48.
de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008, 99: 341-349.PubMedPubMedCentral
49.
Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994, 54: 2771-2777.PubMed
50.
Romero H, Schneider J: Different detection rates of HER-2/NEU overexpression in ovarian carcinoma using two different commercially available detection kits. Eur J Cancer. 1995, 31A: 1020-1021.PubMed
51.
McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM: Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res. 2000, 6: 1854-1864.PubMed
52.
Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S: Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007, 97: 391-397.PubMedPubMedCentral
53.
Gazic B, Pizem J, Bracko M, Cufer T, Borstnar S, Pohar-Marinsek Z, Us-Krasovec M: S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients. Cytopathology. 2008, 19: 294-302.PubMed
54.
Jensen V, Prasad AR, Smith A, Raju M, Wendel CS, Schmelz M, Leyva W, Warneke J, Krouse RS: Prognostic criteria for squamous cell cancer of the skin. J Surg Res. 2010, 159: 509-516.PubMed
55.
56.
Kivela T, Grambsch PM: Evaluation of sampling strategies for modeling survival of uveal malignant melanoma. Invest Ophthalmol Vis Sci. 2003, 44: 3288-3293.PubMed
57.
Breslow NE, Chatterjee N: Design and analysis of two-phase studies with binary outcome applied to Wilms tumour prognosis. Appl Stat. 1999, 48: 457-468.
58.
Gray RJ: Weighted analyses for cohort sampling designs. Lifetime Data Anal. 2009, 15: 24-40.PubMed
59.
Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M: The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res. 2003, 63: 337-341.PubMed
60.
Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C, Nanus DM: Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 2004, 10: 4096-4100.PubMed
61.
Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996, 17: 343-346.PubMed
62.
Clark TG, Altman DG, De Stavola BL: Quantification of the completeness of follow-up. Lancet. 2002, 359: 1309-1310.PubMed
63.
Wu Y, Takkenberg JJ, Grunkemeier GL: Measuring follow-up completeness. Ann Thorac Surg. 2008, 85: 1155-1157.PubMed
64.
Altman DG, De Stavola BL, Love SB, Stepniewska KA: Review of survival analyses published in cancer journals. Br J Cancer. 1995, 72: 511-518.PubMedPubMedCentral
65.
Ceriani RL, Chan CM, Baratta FS, Ozzello L, DeRosa CM, Habif DV: Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer. 1992, 51: 343-354.PubMed
66.
Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M: Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer. 1999, 79: 1752-1760.PubMedPubMedCentral
67.
Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007, 25: 2127-2132.PubMed
68.
Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009, 27: 3757-3763.PubMed
69.
van Walraven C, Davis D, Forster AJ, Wells GA: Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol. 2004, 57: 672-682.PubMed
70.
Beyersmann J, Wolkewitz M, Schumacher M: The impact of time-dependent bias in proportional hazards modelling. Stat Med. 2008, 27: 6439-6454.PubMed
71.
Rochon J: Issues in adjusting for covariates arising postrandomization in clinical trials. Drug Inf J. 1999, 33: 1219-1228.
72.
Fisher LD, Lin DY: Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999, 20: 145-157.PubMed
73.
Andersen P, Skovgaard LT: Regression with linear predictors. 2010, New York, NY: Springer
74.
Cortese G, Andersen PK: Competing risks and time-dependent covariates. Biom J. 2010, 52: 138-158.PubMed
75.
Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002, 360: 1381-1391.PubMed
76.
Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, Shao Y, Aherne W, Houlston R: A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol. 2006, 17: 1810-1817.PubMed
77.
Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009, 27: 5519-5528.PubMed
78.
Schmoor C, Sauerbrei W, Schumacher M: Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med. 2000, 19: 441-452.PubMed
79.
McShane LM, Simon R: Statistical methods for the analysis of prognostic factor studies. Prognostic factors in cancer. Edited by: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind C. 2001, New York, NY: Wiley-Liss, 37-48. 2
80.
Hsieh FY, Lavori PW: Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000, 21: 552-560.PubMed
81.
Gill S, Sargent D: End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?. Oncologist. 2006, 11: 624-629.PubMed
82.
Harrell FE, Lee KL, Matchar DB, Reichert TA: Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985, 69: 1071-1077.PubMed
83.
Schumacher M, Hollander N, Schwarzer G, Sauerbrei W: Prognostic factor studies. Handbook of Statistics in Clinical Oncology. Edited by: Crowley J, Ankerst DP. 2006, Boca Raton, FL: Chapman, 289-334. 2
84.
Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995, 48: 1503-1510.PubMed
85.
Feinstein AR: Multivariable Analysis: an Introduction. 1996, New Haven: Yale University Press
86.
Vittinghoff E, McCulloch CE: Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007, 165: 710-718.PubMed
87.
Lubin JH, Gail MH: On power and sample size for studying features of the relative odds of disease. Am J Epidemiol. 1990, 131: 552-566.PubMed
88.
Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002, 122: 1037-1057.PubMed
89.
Bentzen SM: Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys. 2001, 49: 513-518.PubMed
90.
Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA: A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004, 10: 4-12.PubMed
91.
92.
Concato J, Feinstein AR, Holford TR: The risk of determining risk with multivariable models. Ann Intern Med. 1993, 118: 201-210.PubMed
93.
Bagley SC, White H, Golomb BA: Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol. 2001, 54: 979-985.PubMed
94.
Pocock SJ, Collier TJ, Dandreo KJ, De Stavola BL, Goldman MB, Kalish LA, Kasten LE, McCormack VA: Issues in the reporting of epidemiological studies: a survey of recent practice. BMJ. 2004, 329: 883.PubMedPubMedCentral
95.
Ottenbacher KJ, Ottenbacher HR, Tooth L, Ostir GV: A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. J Clin Epidemiol. 2004, 57: 1147-1152.PubMed
96.
97.
Kho ME, Eva KW, Cook DJ, Brouwers MC: The Completeness of Reporting (CORE) index identifies important deficiencies in observational study conference abstracts. J Clin Epidemiol. 2008, 61: 1241-1249.PubMed
98.
Falagas ME, Grigori T, Ioannidou E: A systematic review of trends in the methodological quality of randomized controlled trials in various research fields. J Clin Epidemiol. 2009, 62: 227-231.PubMed
99.
Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996, 15: 361-387.PubMed
100.
Hosmer DW, Lemeshow S: Applied Logistic Regression. 2000, New York, NY: John Wiley and Sons Ltd
101.
Harrell FE: Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. 2001, New York, NY: Springer
102.
Bradburn MJ, Clark TG, Love SB, Altman DG: Survival analysis part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer. 2003, 89: 605-611.PubMedPubMedCentral
103.
Bradburn MJ, Clark TG, Love SB, Altman DG: Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. Br J Cancer. 2003, 89: 431-436.PubMedPubMedCentral
104.
Clark TG, Bradburn MJ, Love SB, Altman DG: Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer. 2003, 89: 781-786.PubMedPubMedCentral
105.
Clark TG, Bradburn MJ, Love SB, Altman DG: Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003, 89: 232-238.PubMedPubMedCentral
106.
Vittinghoff E, Glidden DV, McCulloch CE, Shiboski SC: Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. 2005, New York, NY: Springer Science and Business Media Inc
107.
Schumacher M, Holländer N, Schwarzer G, Sauerbrei W: Prognostic factor studies. Handbook of Statistics in Clinical Oncology. Edited by: Crowley J, Ankerst DP. 2006, Boca Raton, FL: Chapman & Hall/CRC Press, 289-333. 2
108.
Sauerbrei W, Royston P, Binder H: Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007, 26: 5512-5528.PubMed
109.
Hosmer DW, Lemeshow S, May S: Applied survival analysis: Regression modeling of time-to-event data. 2008, Hoboken, NJ: Wiley-Interscience
110.
Royston P, Sauerbrei W: Multivariable model-building: A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. 2008, Chichester, UK: John Wiley
111.
Dupont WD: Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data. 2009, Cambridge University Press, UK
112.
Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M: The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009, 116: 53-68.PubMed
113.
Altman DG: Preparing to analyse data. Practical statistics for medical research. 1991, London: Chapman and Hall, 122-151.
114.
Blettner M, Sauerbrei W: Influence of model-building strategies on the results of a case-control study. Stat Med. 1993, 12: 1325-1338.PubMed
115.
Mallows C: The zeroth problem. Am Stat. 1998, 52: 1-9.
116.
Chatfield C: Confessions of a pragmatic statistician. J R Stat Soc Ser D-STA. 2002, 51: 1-20.
117.
Bailar JC: How to distort the scientific record without actually lying: truth, and the arts of science. Eur J Oncol. 2006, 11: 217-224.
118.
Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK: Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009, 115: 1021-1027.PubMedPubMedCentral
119.
Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI: Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009, 45: 3291-3297.PubMed
120.
Wolkewitz M, Vonberg RP, Grundmann H, Beyersmann J, Gastmeier P, Barwolff S, Geffers C, Behnke M, Ruden H, Schumacher M: Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crit Care. 2008, 12: R44.PubMedPubMedCentral
121.
Marubini E, Valsecchi M: Analysing Survival Data from Clinical Trials and Observational Studies. 1995, New York, NY: John Wiley and Sons Ltd
122.
Therneau T, Grambsch P: Modeling Survival Data: Extending the Cox Model. 2001, New York, NY: Springer-Verlag New York Inc.
123.
Royston P, Parmar MK: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002, 21: 2175-2197.PubMed
124.
Simon R, Korn EL, McShane LM, Radmacher MD, Wright G, Zhao Y: Design and analysis of DNA microarray investigations. 2004, New York, NY: Springer
125.
Steyerberg EW: Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. 2009, New York, NY: Springer-Verlag
126.
Hastie T, Tibshirani R, Friedman JH: The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2009, New York, NY: Springer-Verlag New York Inc.
127.
Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL: Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003, 5: R242-R249.PubMedPubMedCentral
128.
van Buuren S, Boshuizen HC, Knook DL: Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999, 18: 681-694.PubMed
129.
Kenward MG, Carpenter J: Multiple imputation: current perspectives. Stat Methods Med Res. 2007, 16: 199-218.PubMed
130.
Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009, 338: b2393.PubMedPubMedCentral
131.
132.
Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J, EORTC Lung Cancer Group and Qualoty of Life Unit: Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006, 17: 1698-1704.PubMed
133.
Sauerbrei W: The use of resampling methods to simplify regression models in medical statistics. Appl Stat. 1999, 48: 313-329.
134.
Pace NL: Independent predictors from stepwise logistic regression may be nothing more than publishable P values. Anesth Analg. 2008, 107: 1775-1778.PubMed
135.
Coradini D, Daidone MG, Boracchi P, Biganzoli E, Oriana S, Bresciani G, Pellizzaro C, Tomasic G, Di FG, Marubini E: Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol. 2000, 18: 2702-2709.PubMed
136.
Lutterbach J, Sauerbrei W, Guttenberger R: Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol. 2003, 179: 8-15.PubMed
137.
Gray RJ: Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc. 1992, 87: 942-951.
138.
Abrahamowicz M, MacKenzie TA: Joint estimation of time-dependent and non-linear effects of continuous covariates on survival. Stat Med. 2007, 26: 392-408.PubMed
139.
Sauerbrei W, Royston P, Look M: A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. Biom J. 2007, 49: 453-473.PubMed
140.
Belsley DA, Kuh E, Welsch RE: Regression diagnostics: Identifying influential data and sources of collinearity. 1980, New York, NY: Wiley
141.
Babyak MA: What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004, 66: 411-421.PubMed
142.
Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Hofler H, Keller G: CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer. 2009, 45: 3326-3335.PubMed
143.
Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG: Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008, 107: 249-257.PubMed
144.
Altman DG, Royston P: What do we mean by validating a prognostic model?. Stat Med. 2000, 19: 453-473.PubMed
145.
Altman DG, Vergouwe Y, Royston P, Moons KG: Prognosis and prognostic research: validating a prognostic model. BMJ. 2009, 338: b605.PubMed
146.
Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009, 101: 1446-1452.PubMedPubMedCentral
147.
Davison AC, Hinkley DV: Bootstrap Methods and their Application. 1997, Cambridge University Press, UK
148.
Carpenter J, Bithell J: Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000, 19: 1141-1164.PubMed
149.
Chernick MR: Bootstrap Methods: A Guide for Practitioners and Researchers. 2008, New York, NY: Wiley
150.
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009, 27: 3437-3444.PubMedPubMedCentral
151.
Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS: Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008, 14: 428-434.PubMed
152.
Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G: Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat. 2009, 116: 131-143.PubMed
153.
Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006, 25: 127-141.PubMed
154.
Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX: P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005, 6: 678-686.PubMed
155.
Clark GM, Zborowski DM, Culbertson JL, Whitehead M, Savoie M, Seymour L, Shepherd FA: Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2006, 1: 837-846.PubMed
156.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007, 4: e296.PubMedPubMedCentral
157.
Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du BA, Kiechle-Schwarz M, Pfleiderer A: Cellular DNA content and survival in advanced ovarian carcinoma. Cancer. 1994, 74: 2509-2515.PubMed
158.
Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA: Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer. 2006, 107: 90-98.PubMed
159.
Kommoss F, Pfisterer J, Idris T, Giese E, Sauerbrei W, Schafer W, Thome M, Pfleiderer A: Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol. 1994, 16: 203-210.PubMed
160.
Altman DG: Practical statistics for medical research. 1991, London: Chapman and Hall
161.
162.
Pocock SJ, Clayton TC, Altman DG: Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002, 359: 1686-1689.PubMed
163.
Tzoulaki I, Liberopoulos G, Ioannidis JP: Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009, 302: 2345-2352.PubMed
164.
Kattan MW: Evaluating a new marker's predictive contribution. Clin Cancer Res. 2004, 10: 822-824.PubMed
165.
Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004, 159: 882-890.PubMed
166.
Watermann D, Madjar H, Sauerbrei W, Hirt V, Prompeler H, Stickeler E: Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep. 2004, 11: 905-910.PubMed
167.
Vormittag L, Gleiss A, Scheithauer W, Lang F, Laengle F, Kornek GV: Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. Oncology. 2009, 77: 140-146.PubMed
168.
Efron B, Tibshirani RJ: Introduction to the bootstrap. 1994, Chapman & Hall/CRC Press
169.
Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G: Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res. 2009, 15: 4680-4685.PubMedPubMedCentral
170.
Haffty BG, Yang Q, Moran MS, Tan AR, Reiss M: Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys. 2008, 71: 1006-1013.PubMed
171.
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH: SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009, 15: 4674-4679.PubMedPubMedCentral
172.
Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001, 134: 663-694.PubMed
173.
Gould Rothberg BE, Bracken MB, Rimm DL: Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009, 101: 452-474.PubMed
174.
Whiteley W, Chong WL, Sengupta A, Sandercock P: Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009, 40: e380-e389.PubMed
175.
Mupparapu M, Kim IH: Calcified carotid artery atheroma and stroke: a systematic review. J Am Dent Assoc. 2007, 138: 483-492.PubMed
176.
Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M, Abrams KR, Moreno S, McAllister KS, Palmer S, Kaski JC, Timmis AD, Hingorani AD: Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med. 2010, 7: e1000286.PubMedPubMedCentral
177.
Huber GF, Zullig L, Soltermann A, Roessle M, Graf N, Haerle SK, Studer G, Jochum W, Moch H, Stoeckli SJ: Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer. 2011, 11: 217-218.PubMedPubMedCentral
178.
Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I: Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med. 2010, 8: 19.PubMedPubMedCentral
179.
Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E: Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients. Breast Cancer Res. 2009, 11: R67.PubMedPubMedCentral
180.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D: Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol. 2007, 25: 5194-5202.PubMed
181.
Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Vigano MG, Villa E, Corti A: Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer. 2007, 110: 845-853.PubMed
182.
Stefansson IM, Salvesen HB, Akslen LA: Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004, 22: 1242-1252.PubMed
183.
Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R, Jezequel P: Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer. 2009, 101: 166-173.PubMedPubMedCentral
184.
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009, 115: 1234-1244.PubMed
185.
Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010, 102: 152-160.PubMedPubMedCentral
186.
Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000, 355: 1064-1069.PubMed
187.
Lagakos SW: The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006, 354: 1667-1669.PubMed
188.
189.
Greenland S: Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med. 1983, 2: 243-251.PubMed
190.
Willett WC: The search for truth must go beyond statistics. Epidemiology. 2008, 19: 655-656.PubMed
191.
Royston P, Sauerbrei W: A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2004, 23: 2509-2525.PubMed
192.
Royston P, Sauerbrei W, Ritchie A: Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer. 2004, 90: 794-799.PubMedPubMedCentral
193.
Bonetti M, Gelber RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000, 19: 2595-2609.PubMed
194.
Royston P, Sauerbrei W: Interactions between treatment and continuous covariates: a step toward individualizing therapy. J Clin Oncol. 2008, 26: 1397-1399.PubMed
195.
Donders AR, van der Heijden GJ, Stijnen T, Moons KG: Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006, 59: 1087-1091.PubMed
196.
van der Heijden GJ, Donders AR, Stijnen T, Moons KG: Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol. 2006, 59: 1102-1109.PubMed
197.
Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A: Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol. 2008, 26: 3721-3726.PubMed
198.
Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994, 86: 829-835.PubMed
199.
Holländer N, Sauerbrei W, Schumacher M: Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med. 2004, 23: 1701-1713.PubMed
200.
van Walraven C, Hart RG: Leave 'em alone - why continuous variables should be analyzed as such. Neuroepidemiology. 2008, 30: 138-139.PubMed
201.
Vickers AJ, Lilja H: Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem. 2009, 55: 15-17.PubMed
202.
Taylor JM, Ankerst DP, Andridge RR: Validation of biomarker-based risk prediction models. Clin Cancer Res. 2008, 14: 5977-5983.PubMedPubMedCentral
203.
Royston P, Altman DG: Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Applied Statistics. 1994, 43: 467.
204.
Ioannidis JP: Why most discovered true associations are inflated. Epidemiology. 2008, 19: 640-648.PubMed
205.
Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PJ, Von EE, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE. 2008, 3: e3081.PubMedPubMedCentral
206.
Williamson PR, Gamble C, Altman DG, Hutton JL: Outcome selection bias in meta-analysis. Stat Methods Med Res. 2005, 14: 515-524.PubMed
207.
Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer. 2007, 43: 2559-2579.PubMed
208.
Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP: Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003, 89: 55-64.PubMedPubMedCentral
209.
McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing?. J Natl Cancer Inst. 2005, 97: 1023-1025.PubMed
210.
Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L: Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol. 2011, 8: 171-176.PubMed
211.
Peters J, Mengersen K: Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof. 2008, 31: 370-389.PubMed
212.
Sauerbrei W, Holländer N, Riley RD, Altman DG: Evidence-based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Commun Stat Theory Methods. 2006, 35: 1333-1342.
213.
Rifai N, Altman DG, Bossuyt PM: Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem. 2008, 54: 1101-1103.PubMed
214.
Ntzani EE, Ioannidis JP: Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003, 362: 1439-1444.PubMed
Metadata
Title
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
Authors
Douglas G Altman
Lisa M McShane
Willi Sauerbrei
Sheila E Taube
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2012
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-10-51

Other articles of this Issue 1/2012

BMC Medicine 1/2012 Go to the issue

Minireview

Epilepsy care guidelines for low- and middle- income countries: From WHO mental health GAP to national programs

Research article

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants

Review

Therapy for metastatic melanoma: the past, present, and future

Minireview

Personalized medicine in multiple sclerosis: hope or reality?

Commentary

Location, location, location: the BRMS1 protein and melanoma progression

Commentary

Commentary on the clinical management of metabolic syndrome: why a healthy lifestyle is important